CA
NZ
UK
AU
IND
US
Varex Imaging (Nasdaq: VREX) reported that Teledyne will acquire the company for $18.90 per share in cash, valuing the transaction at approximately $1.1 billion including net debt.
AbCellera (Nasdaq: ABCL) announced that its Phase 2 ABCL635 data in menopausal vasomotor symptoms showed statistically significant week-4 reductions in hot flash frequency and severity after a single 600 mg subcutaneous dose.
Scholar Rock (Nasdaq: SRRK) confirmed that the regulatory review for its apitegromab BLA in spinal muscular atrophy (SMA) is proceeding toward its September 30, 2026 PDUFA date.
QuidelOrtho (Nasdaq: QDEL) shares plummeted as management slashed full-year 2026 revenue guidance to $2.52 billion to $2.60 billion and adjusted EPS guidance to $0.65 to $0.90, down significantly from previous ranges.
Sionna Therapeutics (Nasdaq: SION) announced that its Phase 2a PreciSION CF trial of SION-719 as an add-on to Trikafta failed to meet the primary sweat chloride endpoint, showing only a -1.0 mmol/L placebo-adjusted difference.
MoonLake Immunotherapeutics (Nasdaq: MLTX) announced that its Phase 3 IZAR-1 trial of sonelokimab in biologic-naive psoriatic arthritis patients achieved all Week 16 clinical endpoints.
CVRx (Nasdaq: CVRX) shares closed down 60% at $2.39 despite the company announcing that second-quarter 2026 revenue rose 16% to $15.7 million, with U.S. Barostim sales up 21% and gross margin expanding to 87%.
VivoSim Labs (NASDAQ: VIVS) shares closed up 42% at $0.47 after the company successfully regained compliance with Nasdaq's $2.5 million minimum stockholders' equity mandate.
BioVie (Nasdaq: BIVI) shares closed down 26% at $1 despite the company announcing Phase 2 SUNRISE-PD trial results showing bezisterim enhanced motor and inflammatory markers over a 12-week period.
Cleveland-Cliffs Inc Faces Market Challenges
Please wait processing your request...